Recent news on Mequinol

What’s New in Skin Whitening: Life after hydroquinone  -  Apr 26, 2007
American Chronicle,Even though the FDA approved the combination of mequinol and tretinoin to treat solar lentigines ("age spots" or "liver spots") back in December of 1999,

Barrier Therapeutics Receives FDA Approval for Solage(R) Topical ...  -  May 3, 2007
Genetic Engineering News (press release),Barrier Therapeutics currently markets Solage(R) (mequinol 2%, tretinoin 0.01%) Topical Solution in the United States where it is indicated for the

Barrier Therapeutics to Present at the 2007 Morgan Stanley Global ...  -  26 Apr 2007
Market Wire (press release)...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines.

Barrier Therapeutics to Present at the CIBC World Markets Annual ...  -  Apr 5, 2007
Web Services Journal,...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines.

Barrier Therapeutics Receives Regulatory Approval to Market ...  -  Mar 8, 2007
Genetic Engineering News (press release),...(mequinol 2%, tretinoin 0.01%) Topical Solution for the treatment of solar lentigines, a common condition also known as "age spots" or "liver spots."

Barrier Therapeutics Receives Regulatory Approval to Market ...  -  Mar 8, 2007
Market Wire (press release)...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines.

Barrier Therapeutics Announces Agreement to Co-Promote Vusion ...  -  Mar 6, 2007
PharmaLive.com (press release),...(mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical

Barrier Therapeutics to Present at the SIGnificant Investment ...  -  Feb 22, 2007
SYS-CON Media,...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines.

Barrier Therapeutics to Release Fourth Quarter and Full Year 2006 ...  -  Feb 22, 2007
Genetic Engineering News (press release),...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines.

Barrier Therapeutics Announces Positive Phase 2a Data for Oral ...  -  18 Jan 2007
PipelineReview.com (press release),81.35% white petrolatum) Ointment, for diaper dermatitis complicated by candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution,

Recent Study Shows Favorable Results of Solage(R) (mequinol 2 ...  -  Jan 12, 2007
Genetic Engineering News (press release),Currently, Solage(R) (mequinol 2%, tretinoin 0.01%) Topical Solution is the only combination product approved in the United States for the treatment of

Recent Study Shows Favorable Results of Solagé(R) (mequinol 2 ...  -  Jan 12, 2007
Market Wire (press release)While there have been multiple studies demonstrating that the combination of mequinol 2%, tretinoin 0.01% provides clinically significant improvement in

Barrier Therapeutics to Present at the 25th Annual JPMorgan ...  -  Jan 3, 2007
Market Wire (press release)81.35% white petrolatum) Ointment, for diaper dermatitis complicated by candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution,

Barrier Therapeutics (BRTX) Reports Positive Findings for Solagé ...  -  Jan 12, 2007
StreetInsider.com (subscription),Barrier Therapeutics currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the United States where it is indicated for the treatment

Barrier Therapeutics to Participate in the 2006 RBC Capital ...  -  Dec 6, 2006
Genetic Engineering News (press release),...ketoconazole, USP) Gel, 2%, Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01 ...

Barrier Therapeutics to Present at the Susquehanna Emerging Trends ...  Oct 25, 2006
...ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0%, tretinoin 0.01 ... -Market Wire (press release) Barrier Therapeutics Announces Third Quarter 2006 Financial ...  Oct 31, 2006
...ketoconazole, USP) Gel, 2%, Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01 ... -Genetic Engineering News (press release), Barrier Therapeutics to Present at the UBS Global Life Sciences ...  Sep 19, 2006
...ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0%, tretinoin 0.01 ... -Market Wire

Barrier Therapeutics to Participate in the 2006 RBC Capital ...  -  Dec 6, 2006
Genetic Engineering News (press release),Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution.

Barrier Therapeutics Launches Denavir(R) in Canada  Aug 23, 2006
Canada include VANIQA® (eflornithine hydrochloride) Cream 13.9% for slowing the growth of unwanted facial hair in women and Solagé® (mequinol 2%, tretinoin ... -Market Wire

Barrier Therapeutics to Release Second Quarter 2006 Financial ...  Aug 2, 2006
TM) (ketoconazole, USP) Gel, 2%, Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage® (mequinol 2.0%, tretinoin ... -Yahoo! News

Barrier Therapeutics Receives FDA Approval of Xolegel(TM) Gel for ...  Jul 28, 2006
...products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0%, tretinoin ... -Market Wire

Barrier Therapeutics to Present at the Bank of America 2006 ...  Aug 4, 2006
...ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0%, tretinoin 0.01 ... -Market Wire

Barrier Therapeutics to Present Data on Solagé(R) and Sebazole(TM ...  Jul 27, 2006
...products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0% and ... -Market Wire

Barrier Therapeutics to Present at the CE Unterberg, Towbin ...  Jul 5, 2006
...products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0% and ... -Market Wire



Barrier Therapeutics to Present at Bank of America 2006 Health ...  May 10, 2006
...products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0% and ... - Market Wire





Barrier Therapeutics Acquires the Canadian Distribution Rights For ...  Mar 15, 2006
...markets Vaniqa ® (eflornithine hydrochloride) Cream 13.9% for slowing the growth of unwanted facial hair in women and Solagé ® (mequinol 2%, tretinoin 0.01 ... - PharmaLive.com

Barrier Therapeutics to Present at CIBC World Markets Annual ...  Mar 29, 2006
...products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0% and ... - Market Wire



Barrier Therapeutics Announces Fourth Quarter and Year End 2005 ...  Feb 27, 2006
...of diaper dermatitis complicated by candidiasis which was recently approved by the FDA, the Company currently markets Solagé® (mequinol 2%, tretinoin 0.01 ... - Market Wire

FDA Approves Vusion Ointment for the Treatment of Diaper ...  Feb 17, 2006
...(mequinol 2%, tretinoin 0.01%) Topical Solution in the US and Canada for the treatment of solar lentigines, a common condition also known as "age spots," and ... - PharmaLive.com,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional